DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31

Dermata Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.86−0.00 (-0.01%)

Close on Oct 19, 2026

Market cap: $3.46M
P/E (TTM): –
Dividend yield: –

Dermata Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	2.93	8.20	4.07	5.65	3.46	1.61
Selling, General & Admin	4.84	4.31	–	–	–	–
General & Administrative	–	4.31	3.97	4.02	4.40	1.57
Operating Expenses	7.77	13	8.04	9.67	–	–
Operating Income	-7.77	-13	-8.04	-9.67	-7.86	-3.17
Interest Expense	–	–	–	–	0.05	0.20
Interest & Investment Income	0.22	0.23	0.25	0.06	–	–
Income Tax Expense	–	0	0	0	0	0
Net Income incl. Noncontrolling Interests	–	-12	-7.79	–	–	–
Net Income	-7.56	-12	-7.79	-9.61	-7.90	-3.24
Preferred Dividends	–	–	–	1.20	0.12	0.23
Net Income to Common	–	–	–	-9.61	-10	-3.24
EPS (Basic)(per share)	-8.16	-80.32	-399.90	-139.20	-24.30	-16.90
EPS (Diluted)(per share)	-8.16	-80.32	-399.90	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.93	0.15	–	–	0.43	0.19
Shares Outstanding (Diluted, Weighted)(shares)	0.93	0.15	0.02	–	0.43	0.19
EBITDA	–	–	–	–	-7.86	-3.17
Net Interest Income	–	–	–	0.06	-0.05	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -194.2%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.99
Dividend yield: –